Asia-Pacific Alopecia Treatment (Hair Loss) Market, By Disease Type (Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment), Gender (Male, Female), Form (Topical, Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Alopecia Treatment (Hair Loss) Market Analysis and Size
With every passing decade, hair loss is becoming more prevalent as a result of unhealthy eating habits and sedentary lifestyles. Additionally, hair loss is caused by ageing and hormonal imbalance and a rise in chronic diseases, including cancer, hypertension, arthritis, and depression, mainly among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia results in nearly 95 % of hair loss in men. More than 800,000 people globally are looking for a solution to their hair loss.
Data Bridge Market Research analyses a growth rate in the alopecia treatment (hair loss) market in the forecast period 2023-2030. The expected CAGR of alopecia treatment (hair loss) market is tend to be around 8.10% in the mentioned forecast period. The market was valued at USD 819.07 million in 2022, and it would grow up to USD 1527.3 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Alopecia Treatment (Hair Loss) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Non‒Cicatricial Alopecia, Traction Alopecia, Ciatricial Alopecia, Others), Treatment (Localized Therapies, Medical Devices, Systemic Therapies, Herbal Treatment), Gender (Male, Female), Form (Topical, Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (U.S.), Endo International plc (Ireland), Zydus Group (India), Abbott (U.S.), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Perrigo Company plc (Ireland), Curallux, LLC. (U.S.), DR. KURT WOLFF GMBH & CO. KG (Germany), WOCKHARDT (India)
|
|
Market Opportunities
|
|
Market Definition
Alopecia is a kind of hair loss that is caused by particular medical illnesses or nutritional disorders. Hair loss is becoming more prevalent as a result of sedentary lifestyles and unhealthy eating habits. Additionally, hair loss is caused by ageing and hormonal imbalance and a rise in chronic diseases, including cancer, hypertension, arthritis, and depression, mainly among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia results for nearly 95 % of hair loss in men. More than 800,000 people globally are looking for a solution to their hair loss.
Asia-Pacific Alopecia Treatment (Hair Loss) Market Dynamics
Drivers
- Increasing Incidence of Hair Loss
The increasing prevalence of hair loss is projected to boost the growth of the alopecia treatment (hair loss) market. For instance, as per the 2019 survey released by the China Association of Health Promotion and Education (CAHEP), 1 out of 6 Chinese people, or around 250 million people, are suffering from hair loss. As per the Journal of Clinical and Diagnostic Research (JCDR), about 60% of the population suffers from hair thinning, with pattern hair loss being the most usual kind of hair loss in both men and women. Additionally, nearly 2% of the entire population, irrespective of gender, is at high risk of acquiring alopecia treatment (hair loss) in their lifetime. It has been witnessed that most of the men across China, are generally bald and termed as a bald wave, which has curated a new beneficial business within the hair loss treatment industry. Further statistics from health departments witness that China's urban residents' consumption of hair care is increasing each year at an increasing pace of 30 %, which over the upcoming years, is anticipated to increase the hair nutrition, restoration, and transplantation business. Thus, it boosts the market growth.
Opportunities
- Wide Adoption of Platelet-Rich Plasma Therapy
Increasing adoption of platelet-rich plasma therapy is anticipated to offer huge growth opportunities for players in the market. For instance, several researchers from Plastic and Reconstructive Surgery, “Tor Vergata” University, Italy, stated that platelet-rich plasma is considered a safe and effective alternative to treat hair loss compared with Minoxidil and Finasteride in April 2020. Thus, this boosts the market growth.
- Increasing Adoption of Organic Hair Products
Traditional natural and herbal based products are more incident for the treatment of hair loss problems in countries such as India and China. The organic hair loss products are most likely to be pushed by males, because they are more susceptible to hair losses. In general, the hair type among Asians is not quite as vulnerable to genetic thinning as western hair, but that affects a million men and women with hair loss. The data from the US and Belgravie Centre suggested that in China 21% of men have genetic hair loss, while the figure for women estimates 6%. Thus, it increases the market growth.
Restraints/Challenges
- Limited Efficacy of Hair Loss Drugs
Limited efficacy and lack of evidence suggest that clinical efficacy of the existing hair loss drugs is hindering market growth. For instance, current topical hair loss treatments are widely available in the market such as minoxidil are not 100% effective for the treatment of alopecia. However, it has been clinically proven to decrease the progression of hair loss.
- Lack of Reimbursement Policies
There is a lack of reimbursement for hair loss treatment services, which are expected to restrict the market growth. Both public and private payers do not reimburse majority of the laser treatment services. The cost of such services varies greatly and there cannot be any standardization.
This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the alopecia treatment (hair loss) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2021, Pfizer announced the positive results from phase 2b/3 trial of ritlecitinib in alopecia treatment. Ritlecitinib is the first of a new class of covalent kinase inhibitors that target Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family with great selectivity. Ritlecitinib is experimented with to prevent the function of signaling molecules and immune cells that widely contribute to hair loss in people with alopecia treatment
Asia-Pacific Alopecia Treatment (Hair Loss) Market Scope
The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Non‒Cicatricial Alopecia
- Traction Alopecia
- Ciatricial Alopecia
- Others
Treatment
- Localized Therapies
- Medical Devices
- Systemic Therapies
- Herbal Treatment
Gender
- Male
- Female
Form
- Topical
- Oral
- Parenteral
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Alopecia Treatment (Hair Loss) Market Regional Analysis/Insights
The alopecia treatment (hair loss) market is analyzed and market size insights and trends are provided by disease type, treatment, gender, form, end user and distribution channel as referenced above.
The major countries covered in the alopecia treatment (hair loss) market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan is expected to dominate in the market in the Asia-Pacific market because of rapidly increasing male population and growing awareness associated with the treatment of hair loss.
China is one of the fastest growing countries due to rapidly changing lifestyle, medical device manufacturing, and high usage of herbal supplements.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of asia-pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Alopecia Treatment (Hair Loss) Market Share Analysis
The alopecia treatment (hair loss) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, asia-pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to alopecia treatment (hair loss) market
Key players operating in the alopecia treatment (hair loss) market include:
- Johnson & Johnson Private Limited (U.S.)
- GSK plc (U.K.)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Cipla Inc. (U.S.)
- Endo International plc (Ireland)
- Zydus Group (India)
- Abbott (U.S.)
- Aurobindo Pharma (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Perrigo Company plc (Ireland)
- Curallux, LLC. (U.S.)
- DR. KURT WOLFF GMBH & CO. KG (Germany)
- WOCKHARDT (India)
SKU-